+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antifungal Drugs Market Size, Share & Trends Analysis Report by Drug Class (Azoles, Echinocandins, Polyenes, Allylamines), Indication, Dosage Form, Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
Antifungal Drugs Market Size, Share & Trends Analysis Report by Drug Class (Azoles, Echinocandins, Polyenes, Allylamines), Indication, Dosage Form, Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
New

Antifungal Drugs Market Size, Share & Trends Analysis Report by Drug Class (Azoles, Echinocandins, Polyenes, Allylamines), Indication, Dosage Form, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 150 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 4751747
Description Jump to:
The Antifungal Drugs Market was valued at USD 16.35 billion in 2024, and is projected to reach USD 20.52 billion by 2030, rising at a CAGR of 3.92%. The increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, the rise in the adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in an increased incidence of fungal infections in recent years.

According to statistics published by the Centers for Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to the high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to the high prevalence of mycological infections around the globe.

The government authorities in many countries had ordered nationwide lockdowns in order to contain the spread of COVID-19. Similarly, health systems in a number of countries around the world were having trouble maintaining their supply chains. The slowness of the supply chain has also impacted the demand for antifungal medications. As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, the rise in the geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2030 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Antifungal Drugs Market Report Highlights

  • The Azoles drug class segment dominated the market and accounted for a revenue share of 47.57% in 2024. This dominance is attributed to the influence of key therapeutic agents, including noxafil, vfend, diflucan, and cresemba.
  • The Candidiasis segment held the largest market share in 2024 due to rising incidence of the disease in immunocompromised patients and high rate of recurrent infections.
  • Aspergillosis is expected to register significant CAGR during the forecast period. Aspergillosis is an infection caused by mold called aspergillosis, which usually affects the respiratory system.
  • Oral drugs dosage form led the market in 2024. This is attributed to the fact that certain antifungal medications are designed for oral administration to ensure proper ingestion.
  • Hospital pharmacies led the market in 2024. Hospital pharmacies play a key role in ensuring immediate access to crucial medications. They serve both out-patient and in-patient services, facilitating the seamless treatment of fungal infections.
  • North America dominated the market and accounted for 40.62% share in 2024. This region dominance is attributed to the highly developed healthcare infrastructure, better affordability, and increasing awareness.
  • Asia-Pacific is anticipated to witness significant growth during the forecast period. This is owing to the presence of large target population, developing healthcare facilities, and increase in investments by leading market players.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Indication
1.2.3. Dosage Form
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Antifungal Drugs Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Antifungal Drugs Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Azoles
4.4.1. Azoles Market, 2018-2030 (USD Million)
4.5. Echinocandins
4.5.1. Echinocandins Market, 2018-2030 (USD Million)
4.6. Polyenes
4.6.1. Polyenes Market, 2018-2030 (USD Million)
4.7. Allylamines
4.7.1. Allylamines Market, 2018-2030 (USD Million)
4.8. Others
4.8.1. Other Drug Class Market, 2018-2030 (USD Million)
Chapter 5. Antifungal Drugs Market: Indication Business Analysis
5.1. Indication Market Share, 2024 & 2030
5.2. Indication Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
5.4. Dermatophytosis
5.4.1. Dermatophytosis Market, 2018-2030 (USD Million)
5.5. Aspergillosis
5.5.1. Aspergillosis Market, 2018-2030 (USD Million)
5.6. Candidiasis
5.6.1. Candidiasis Market, 2018-2030 (USD Million)
5.7. Others
5.7.1. Others Market, 2018-2030 (USD Million)
Chapter 6. Antifungal Drugs Market: Dosage Form Business Analysis
6.1. Dosage Form Market Share, 2024 & 2030
6.2. Dosage Form Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
6.4. Oral Drugs
6.4.1. Oral Drugs Market, 2018-2030 (USD Million)
6.5. Ointments
6.5.1. Ointments Market, 2018-2030 (USD Million)
6.6. Powders
6.6.1. Powders Market, 2018-2030 (USD Million)
6.7. Others
6.7.1. Others Market, 2018-2030 (USD Million)
Chapter 7. Antifungal Drugs Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies Market, 2018-2030 (USD Million)
7.6. Other Pharmacies
7.6.1. Other Pharmacies Market, 2018-2030 (USD Million)
Chapter 8. Antifungal Drugs Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
8.4. North America
8.4.1. North America Antifungal Drugs Market Estimates and Forecasts, By Country, 2018-2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Framework
8.4.2.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Framework
8.4.3.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Framework
8.4.4.5. Mexico Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5. Europe
8.5.1. Europe Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Framework
8.5.2.5. Uk Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Framework
8.5.3.5. Germany Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement Framework
8.5.4.5. France Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Regulatory Framework
8.5.5.4. Reimbursement Framework
8.5.5.5. Italy Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Target Disease Prevalence
8.5.6.3. Regulatory Framework
8.5.6.4. Reimbursement Framework
8.5.6.5. Spain Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. Target Disease Prevalence
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement Framework
8.5.7.5. Denmark Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. Target Disease Prevalence
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement Framework
8.5.8.5. Sweden Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. Target Disease Prevalence
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement Framework
8.5.9.5. Norway Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Framework
8.6.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Framework
8.6.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Framework
8.6.4.5. India Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Framework
8.6.5.5. Australia Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement Framework
8.6.6.5. South Korea Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Target Disease Prevalence
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement Framework
8.6.7.5. Thailand Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Target Disease Prevalence
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement Framework
8.7.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Target Disease Prevalence
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement Framework
8.7.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Antifungal Drugs Market Estimates and Forecasts, 2017-2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Target Disease Prevalence
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement Framework
8.8.2.5. South Africa Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Target Disease Prevalence
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement Framework
8.8.3.5. Saudi Arabia Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Target Disease Prevalence
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement Framework
8.8.4.5. UAE Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Target Disease Prevalence
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement Framework
8.8.5.5. Kuwait Antifungal Drugs Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Novartis AG
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Pfizer, Inc.
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Bayer AG
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Sanofi
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Merck & Co., Inc.
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. GSK plc.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Abbott
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. GLENMARK
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Enzon Pharmaceuticals, Inc.
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Astellas Pharma, Inc.
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global Antifungal drugs market, by region, 2018-2030 (USD Million)
Table 4. Global antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 5. Global antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 6. Global antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 7. Global antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 8. North America antifungal drugs market, by country, 2018-2030 (USD Million)
Table 9. North America antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 10. North America antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 11. North America antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 12. North America antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 13. U.S. antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 14. U.S. antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 15. U.S. antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 16. U.S. antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 17. Canada antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 18. Canada antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 19. Canada antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 20. Canada antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 21. Mexico antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 22. Mexico antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 23. Mexico antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 24. Mexico antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 25. Europe antifungal drugs market, by country, 2018-2030 (USD Million)
Table 26. Europe antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 27. Europe antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 28. Europe antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 29. Europe antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 30. UK antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 31. UK antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 32. UK antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 33. UK antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 34. Germany antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 35. Germany antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 36. Germany antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 37. Germany antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 38. France antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 39. France antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 40. France antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 41. France antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 42. Italy antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 43. Italy antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 44. Italy antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 45. Italy antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 46. Spain antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 47. Spain antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 48. Spain antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 49. Spain antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 50. Norway antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 51. Norway antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 52. Norway antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 53. Norway antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 54. Denmark antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 55. Denmark antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 56. Denmark antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 57. Denmark antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 58. Sweden antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 59. Sweden antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 60. Sweden antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 61. Sweden antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 62. Asia Pacific antifungal drugs market, by country, 2018-2030 (USD Million)
Table 63. Asia Pacific antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 64. Asia Pacific antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 65. Asia Pacific antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 66. Asia Pacific antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 67. Japan antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 68. Japan antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 69. Japan antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 70. Japan antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 71. China antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 72. China antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 73. China antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 74. China antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 75. India antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 76. India antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 77. India antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 78. India antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 79. Australia antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 80. Australia antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 81. Australia antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 82. Australia antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 83. South Korea antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 84. South Korea antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 85. South Korea antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 86. South Korea antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 87. Thailand antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 88. Thailand antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 89. Thailand antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 90. Thailand antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 91. Latin America antifungal drugs market, by country, 2018-2030 (USD Million)
Table 92. Latin America antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 93. Latin America antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 94. Latin America antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 95. Latin America antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 96. Brazil antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 97. Brazil antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 98. Brazil antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 99. Brazil antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 100. Argentina antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 101. Argentina antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 102. Argentina antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 103. Argentina antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 104. Middle East & Africa antifungal drugs market, by country, 2018-2030 (USD Million)
Table 105. Middle East & Africa antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 106. Middle East & Africa antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 107. Middle East & Africa antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 108. Middle East & Africa antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 109. South Africa antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 110. South Africa antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 111. South Africa antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 112. South Africa antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 113. Saudi Arabia antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 114. Saudi Arabia antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 115. Saudi Arabia antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 116. Saudi Arabia antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 117. UAE antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 118. UAE antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 119. UAE antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 120. UAE antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
Table 121. Kuwait antifungal drugs market, by drug class, 2018-2030 (USD Million)
Table 122. Kuwait antifungal drugs market, by indication, 2018-2030 (USD Million)
Table 123. Kuwait antifungal drugs market, by dosage form, 2018-2030 (USD Million)
Table 124. Kuwait antifungal drugs market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Antifungal drugs market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Segment snapshot
Figure 10 Competitive landscape
Figure 11 Antifungal drugs market dynamics
Figure 12 Antifungal drugs market: Porter’s five forces analysis
Figure 13 Antifungal drugs market: PESTLE analysis
Figure 14 Drug Class market, 2018-2030 (USD Million)
Figure 15 Azoles market, 2018-2030 (USD Million)
Figure 16 Echinocandins market, 2018-2030 (USD Million)
Figure 17 Polyenes market, 2018-2030 (USD Million)
Figure 18 Allylamines market, 2018-2030 (USD Million)
Figure 19 Others market, 2018-2030 (USD Million)
Figure 20 Indication market, 2018-2030 (USD Million)
Figure 21 Dermatophytosis market, 2018-2030 (USD Million)
Figure 22 Aspergillosis market, 2018-2030 (USD Million)
Figure 23 Candidiasis market, 2018-2030 (USD Million)
Figure 24 Others market, 2018-2030 (USD Million)
Figure 25 Dosage Form market, 2018-2030 (USD Million)
Figure 26 Oral Drugs market, 2018-2030 (USD Million)
Figure 27 Ointments market, 2018-2030 (USD Million)
Figure 28 Powders market, 2018-2030 (USD Million)
Figure 29 Others market, 2018-2030 (USD Million)
Figure 30 Distribution Channel market, 2018-2030 (USD Million)
Figure 31 Hospital pharmacies market, 2018-2030 (USD Million)
Figure 32 Retail pharmacies market, 2018-2030 (USD Million)
Figure 33 Other pharmacies market, 2018-2030 (USD Million)
Figure 34 Antifungal drugs market revenue, by region
Figure 35 Regional marketplace: Key takeaways
Figure 36 North America antifungal drugs market, 2018-2030 (USD Million)
Figure 37 U.S. country dynamics
Figure 38 U.S. antifungal drugs market, 2018-2030 (USD Million)
Figure 39 Canada country dynamics
Figure 40 Canada antifungal drugs market, 2018-2030 (USD Million)
Figure 41 Mexico country dynamics
Figure 42 Mexico antifungal drugs market, 2018-2030 (USD Million)
Figure 43 Europe antifungal drugs market, 2018-2030 (USD Million)
Figure 44 UK country dynamics
Figure 45 UK antifungal drugs market, 2018-2030 (USD Million)
Figure 46 Germany country dynamics
Figure 47 Germany antifungal drugs market, 2018-2030 (USD Million)
Figure 48 France country dynamics
Figure 49 France antifungal drugs market, 2018-2030 (USD Million)
Figure 50 Italy country dynamics
Figure 51 Italy antifungal drugs market, 2018-2030 (USD Million)
Figure 52 Spain country dynamics
Figure 53 Spain antifungal drugs market, 2018-2030 (USD Million)
Figure 54 Norway country dynamics
Figure 55 Norway antifungal drugs market, 2018-2030 (USD Million)
Figure 56 Sweden country dynamics
Figure 57 Sweden antifungal drugs market, 2018-2030 (USD Million)
Figure 58 Denmark country dynamics
Figure 59 Denmark antifungal drugs market, 2018-2030 (USD Million)
Figure 60 Asia Pacific antifungal drugs market, 2018-2030 (USD Million)
Figure 61 Japan country dynamics
Figure 62 Japan antifungal drugs market, 2018-2030 (USD Million)
Figure 63 China country dynamics
Figure 64 China antifungal drugs market, 2018-2030 (USD Million)
Figure 65 India country dynamics
Figure 66 India antifungal drugs market, 2018-2030 (USD Million)
Figure 67 Australia country dynamics
Figure 68 Australia antifungal drugs market, 2018-2030 (USD Million)
Figure 69 South Korea country dynamics
Figure 70 South Korea antifungal drugs market, 2018-2030 (USD Million)
Figure 71 Thailand country dynamics
Figure 72 Thailand antifungal drugs market, 2018-2030 (USD Million)
Figure 73 Latin America antifungal drugs market, 2018-2030 (USD Million)
Figure 74 Brazil country dynamics
Figure 75 Brazil antifungal drugs market, 2018-2030 (USD Million)
Figure 76 Argentina country dynamics
Figure 77 Argentina antifungal drugs market, 2018-2030 (USD Million)
Figure 78 MEA antifungal drugs market, 2018-2030 (USD Million)
Figure 79 South Africa country dynamics
Figure 80 South Africa antifungal drugs market, 2018-2030 (USD Million)
Figure 81 Saudi Arabia country dynamics
Figure 82 Saudi Arabia antifungal drugs market, 2018-2030 (USD Million)
Figure 83 UAE country dynamics
Figure 84 UAE antifungal drugs market, 2018-2030 (USD Million)
Figure 85 Kuwait country dynamics
Figure 86 Kuwait antifungal drugs market, 2018-2030 (USD Million)
Figure 87 Company categorization
Figure 88 Company market position analysis, 2024
Figure 89 Strategic framework

Companies Mentioned

The major companies featured in this Antifungal Drugs market report include:
  • Novartis AG
  • Pfizer, Inc.
  • Bayer AG
  • Sanofi
  • Merck & Co., Inc.
  • GSK plc
  • Abbott
  • Glenmark
  • Enzon Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.

Table Information

Report AttributeDetails
No. of Pages150
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 16.35 Billion
Forecasted Market Value ( USD ) by 2030 $ 20.52 Billion
Compound Annual Growth Rate3.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antifungal Drugs Market by Drug Type, Route Of Administration, Dosage Form, Therapeutic Application, Distribution Channel, End User - Global Forecast to 2030 - Product Image

Antifungal Drugs Market by Drug Type, Route Of Administration, Dosage Form, Therapeutic Application, Distribution Channel, End User - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Antifungal Drugs Market Report by Drug Class, Indication, and Region 2024-2032 - Product Image

Antifungal Drugs Market Report by Drug Class, Indication, and Region 2024-2032

  • Report
  • 147 Pages
  • Global
From
Antifungal Drugs - Global Strategic Business Report - Product Image

Antifungal Drugs - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Antifungals Market Report 2025 - Product Image

Antifungals Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Anti-Infective Agents Market Size, Share & Trends Analysis Report By Type (Antibacterial, Antiviral, Antifungal & Antiparasitic), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Anti-Infective Agents Market Size, Share & Trends Analysis Report By Type (Antibacterial, Antiviral, Antifungal & Antiparasitic), By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 130 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.